ActoGeniX receives IWT grant for treatment of oral mucositis and starts clinical trial with AG013
The IWT grant will be used to fund further development of AG013, including a phase 1B clinical study which ActoGeniX has initiated this month. This is the second clinical development program in ActoGeniX’s portfolio, next to a phase 2A clinical trial with AG011 in inflammatory bowel disease, for which results are expected in October 2009.
In May of this year, the United States Food and Drug Administration (FDA) approved ActoGeniX’s Investigational New Drug (IND) application, allowing the Company to initiate a phase 1B clinical trial with AG013 in cancer patients at risk of developing oral mucositis. Meanwhile, ActoGeniX has started this clinical study in collaboration with six reputed oncology centers in the US. The primary aim of the study is to evaluate safety and tolerability of AG013, but it will also allow collection of initial efficacy data.
Dr. Mark Vaeck, CEO of ActoGeniX, comments: “This IWT grant is a strong endorsement of our AG013 program, and allows ActoGeniX to rapidly move forward to develop this product in the clinic. Oral mucositis is a significant challenge in the treatment of cancer, as close to 50% of all cancer patients undergoing chemotherapy or radiation therapy are developing this condition. With AG013 we look forward to offer new and more effective treatment perspectives for these patients.”
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.